Diabetes device makers fall after Lilly's weight-loss drug cuts diabetes risk

Tandem Diabetes Care

20/08/2024 19:14

** Shares of diabetes device makers fall between 6% and 8%
    ** Eli Lilly  LLY.N  says its weight-loss drug, Zepbound,
drastically cut the risk of developing type 2 diabetes in
overweight or obese pre-diabetic adults after three years of
weekly injections
    ** LLY shares up 2.47% at $944.57
    ** Shares of Dexcom  DXCM.O , which manufactures continuous
glucose monitoring (CGM) systems, fall 5.96% to $73.05
     ** Insulin pump makers Insulet Corp's  PODD.O  shares fell
6.91% to $182.39, and Tandem Diabetes Care  TNDM.O  fell 8.07%
to $42.02
    ** DXCM down ~41%, PODD down ~16%, while TNDM up ~42% YTD 

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))